Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease

JAMA Neurology

Volumn 74, Issue 4, 2017, Pages 427-436

  Xia, Chenjie ^a   Makaretz, Sara J ^a   Caso, Christina ^a   McGinnis, Scott ^a   Gomperts, Stephen N ^a   Sepulcre, Jorge ^a   Gomez Isla, Teresa ^a   Hyman, Bradley T ^a   Schultz, Aaron ^a   Vasdev, Neil ^a   Johnson, Keith A ^a   Dickerson, Bradford C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; BIOLOGICAL MARKER; FLORTAUCIPIR F 18; PITTSBURGH COMPOUND B; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX ATROPHY; BRAIN REGION; CASE STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; CORRELATIONAL STUDY; CORTICAL THICKNESS (BRAIN); CORTICOBASAL DEGENERATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIMARY PROGRESSIVE APHASIA; PROTEIN PHOSPHORYLATION; RADIOISOTOPE DISTRIBUTION; ATROPHY; BRAIN CORTEX; COMPLICATION; DIAGNOSTIC IMAGING; IMAGE PROCESSING; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY;

ALZHEIMER DISEASE; ATROPHY; CARBOLINES; CEREBRAL CORTEX; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TAU PROTEINS;

EID: 85017589110     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.5755     Document Type: Article

References (40)

1. Galton CJ, Patterson K, Xuereb J.H., Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimagingand pathological study of 13 cases. Brain. 2000; 123(pt 3):484-498.
2. Montine TJ, Phelps CH, Beach T.G., et al; National Instituteon Aging; Alzheimer's Association. National Institute on Aging-Alzheimer's Association guidelines fortheneuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012; 123(1):1-11.
3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992; 42(3, pt1): 631-639.
4. Nelson PT, Alafuzoff I, Bigio E.H., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71(5):362-381.
5. Wolk DA. Amyloid imaging in atypical presentations of Alzheimer's disease. Curr Neurol Neurosci Rep. 2013; 13(12):412.
6. Hof PR, Bouras C, Constantinidis J., Morrison JH. Balint's syndrome in Alzheimer's disease: specific disruption of the occipito-parietal visual pathway. Brain Res. 1989; 493(2):368-375.
7. Johnson JK, Head E, Kim R., Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999; 56 (10):1233-1239.
8. Gefen T, Gasho K, Rademaker A., et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. Brain. 2012; 135 (pt 5):1554-1565.
9. Villemagne VL, Fodero-Tavoletti MT, Masters C.L., Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015; 14(1):114-124.
10. Sapolsky D, Bakkour A, Negreira A., et al. Cortical neuroanatomic correlates of symptom severity in primary progressive aphasia. Neurology. 2010; 75(4):358-366.
11. McKhann GM, Knopman DS, Chertkow H, et al The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3): 263-269.
12. Mendez MF, Ghajarania M, Perryman KM Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord. 2002; 14(1):33-40.
13. Crutch SJ, Schott JM, Rabinovici G.D., et al. Shining a light on posterior cortical atrophy. Alzheimers Dement. 2013; 9(4):463-465.
14. Gorno-Tempini M.L., Hillis AE, Weintraub S, et al Classification of primary progressive aphasia and its variants. Neurology. 2011; 76(11):1006-1014.
15. Armstrong MJ, Litvan I, Lang A.E., et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80(5):496-503.
16. 18F]T807. J Labelled Comp Radiopharm. 2013; 56 (14):736-740.
17. 11C]-6-OH-BTA-1). J Labelled Comp Radiopharm. 2004; 47:679-682. doi:10.1002/jlcr.854
18. Johnson KA, Schultz A, Betensky R.A., et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016; 79 (1):110-119.
19. Becker JA, Hedden T, Carmasin J., et al. Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol. 2011; 69(6):1032-1042.
20. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990; 10(5): 740-747.
21. Dickerson BC, Fenstermacher E, Salat D.H., et al. Detection of cortical thickness correlates of cognitive performance: reliability across MRI scan sessions, scanners, and field strengths. Neuroimage. 2008; 39(1):10-18.
22. Desikan RS, Ségonne F, Fischl B., et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006; 31(3): 968-980.
23. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-259.
24. Klunk WE, Engler H, Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3): 306-319.
25. Chien DT, Bahri S, Szardenings A.K., et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013; 34 (2):457-468.
26. Marquié M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015; 78(5): 787-800.
27. Smith R, Wibom M, Olsson T., et al. Posterior accumulation of tau and concordant hypometabolism in an early-onset Alzheimer's disease patient with presenilin-1 mutation. J Alzheimers Dis. 2016; 51(2):339-343.
28. Pascual B, Masdeu JC Tau, amyloid, and hypometabolism in the logopenic variant of primary progressive aphasia. Neurology. 2016; 86 (5):487-488.
29. Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016; 139(pt 5):1551-1567.
30. Ossenkoppele R, Schonhaut DR, Baker S.L., et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015; 77(2):338-342.
31. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65(4):403-413.
32. Silverman DHS, Small GW, Chang C.Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001; 286(17):2120-2127.
33. Silbert LC, Quinn JF, Moore M.M., et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003; 61(4):487-492.
34. Gómez-Isla T., Hollister R, West H., et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997; 41(1):17-24.
35. Whitwell JL, Josephs KA, Murray M.E., et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008; 71(10):743-749.
36. Desikan RS, McEvoy LK, Thompson W.K., et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011; 70(4): 657-661.
37. Dickerson BC, Wolk DA; Alzheimer's Disease Neuroimaging Initiative. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Front Aging Neurosci. 2013; 5:55.
38. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970; 11(3):205-242.
39. Johnson KA, Minoshima S, Bohnen N.I., et al. Guidelines for brain amyloid imaging published. J Nucl Med. 2013; 54:476-490.
40. Wolk DA, Price JC, Madeira C, et al Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012; 8(5):389-398.